<DOC>
	<DOCNO>NCT00040105</DOCNO>
	<brief_summary>The goal clinical research study find high safe dose drug ZarnestraTM ( R115777 ) Gleevec ( imatinib mesylate ) give combination treatment chronic myelogenous leukemia ( CML ) chronic phase . The effect combination leukemia also study .</brief_summary>
	<brief_title>Zarnestra Gleevec Chronic Phase Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>R115777 new drug block function enzyme important making protein work . One important target enzyme protein make cell become cancer . Imatinib mesylate drug block function protein come Philadelphia chromosome . The Philadelphia chromosome abnormality chromosomes 9 22 change blood cell leukemia cell . Before treatment start , participant physical exam , blood test ( About 3 tube , 2 teaspoon ) , bone marrow biopsy . The bone marrow remove large needle . Participants study take imatinib mesylate mouth every day long stay study , mean long work . Participants also take R115777 twice day 2 week . This repeat every 3 week . The amount medication participant take depend enter study . The dos slowly increase participant participant high dose cause serious side effect find . Participants ask visit doctor physical exam measurement vital sign . The frequency doctor visit vary depend physical condition . Blood test ( 2 teaspoon ) do every week first 3 week treatment . Blood test do every 8-12 week length study , need . The blood sample use routine lab test . A bone marrow sample also take check measure cell related disease every 3 month first year every 6-12 month . Participants stay study long treatment consider beneficial . Participants take study disease get bad intolerable side effect occur . This investigational study . The FDA authorize use imatinib mesylate patient CML . It combination imatinib mesylate R115777 experimental . R115777 authorize investigational use . A maximum 30 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients 16 year old Philadelphia chromosome ( Ph ) BCR/ABLpositive CML ( determine cytogenetics , FISH , PCR ) eligible candidate know regimen protocol treatment higher efficacy priority . Patients must chronic phase CML . Patients must fail therapy imatinib mesylate . Failure define : 1 ) patient fail achieve lose complete hematologic remission 3 month start therapy imatinib mesylate , 2 ) patient fail achieve lose least minimal cytogenetic response 6 month therapy imatinib mesylate , 3 ) patient fail achieve lose major cytogenetic response 12 month therapy imatinib mesylate Chronic phase define follow feature : 1 ) blast peripheral blood bone marrow &lt; 10 % , 2 ) basophil PB BM &lt; 20 % , 3 ) platelet &gt; 100 x 10 ( 9 ) /L , 4 ) absence clonal evolution Patients must sign informed consent Performance status &lt; /= 2 Zubrod scale Patients must adequate hepatic function ( bilirubin &lt; /= 2.0 mg/dl ) renal function ( creatinine &lt; /=2 mg/dl ) WBC &lt; /= 30 x 10 ( 9 ) /L . Patients may receive Hydroxyurea ( similar agent ) bring WBC level . Hydroxyurea ( equivalent ) must discontinue 24 hour start therapy . Patients childbearing potential practice effective method contraception . Patients 16 year age . Pregnant nursing female exclude .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Chronic Myelogenous Leukemia , Chronic Phase</keyword>
	<keyword>R115777</keyword>
	<keyword>Zarnestra</keyword>
	<keyword>Tipifarnib</keyword>
	<keyword>Imatinib Mesylate</keyword>
	<keyword>Gleevec</keyword>
	<keyword>Imatinib</keyword>
	<keyword>STI571</keyword>
	<keyword>NSC-716051</keyword>
</DOC>